Milea Timbergen

168 Table 2. (continued) First author, year of publication, inclusion. period Total N FAP/ Gardner N P/R total ASG N P/R ASG Median age ASG Sex M/F ASG Site ASG Median FU (r/ IQR/95% CI) ASG PD SD PR CR NS Shift to AT AT Reported concurrent use of NSAID’s and/or hormonal therapy during the AS approach Non-narcotic analgesics and non-steroidal anti-inflammatory drugs (NSAID’s) were offered to symptomatic patients Briand, 2014 8 NS 73 0 52/21 55 31/24 35 20/35 42 EG 1 HN 12 TR 73 months 7 42 NS 5 1 5/55 3 SG 1 ST 1 SG + RT With or without administration of NSAID’s Penel, 2017 6 2010-2016 771 NS 771/0 388 388/0 NS 388 NS 388 NS NS 117 NS NS NS 271 71/338 3 CrT 2 SG 61 ST 1 RF 4 RT Conversion to hormonal therapy was not considered failure of AS treatment Turner, 2019 38 2004-2015 103 0 103/0 50 50/0 41 m 13/37 14 AW 20 EG 3 HN 3 IA 8 TR 2 NS NS 21 29 0 0 0 19/50 9 SG 9 RT 1 SG+ RT + ST ASG, active surveillance group; AT, active treatment; AW, abdominal wall; CrT, cryotherapy; EG, extremity/girdles; IA, intra-abdominal; IQR, interquartile range; NA, not applicable; NS, not specified; NSAID’s, non-steroidal anti-inflammatory drugs; P, primary disease; R, recurrent disease; RF, radiofrequency; RT, radiotherapy; SG, surgery; ST, systemic treatment; TTI, time to intervention; TR, trunk r, range a including residual tumours; b only group A, B and C included in this table; c only group A (primary tumours) and C (recurrent tumours) included in this table; d n=51 shift due to tumour growth, symptom escalation or patient preference for intervention; e n = 72 received AS, n = 37 patients had available Response Evaluation Criteria In Solid Tumors (RECIST); m mean value instead of median 6